Top 50 Biotechnology VC (Venture Capital) Funds in Ireland in February 2025

Investor	Biotechnology Ireland investments
Enterprise Ireland	30
SOSV	19
Western Development Commission	12
Irrus Investments	7
Kernel Capital	7
AIB Seed Capital Fund	6
Fountain Healthcare Partners	6
Atlantic Bridge	5
Seroba Life Sciences	5
European Investment Bank	4
HBAN	4
HBAN Medtech Syndicate	4
Atlantic Bridge University Fund	3
Act Venture Capital	3
Boole Investment Syndicate	3
The Yield Lab Europe	3
Furthr VC	3
SVG Ventures	2
Enterprise Equity	2
Ascentifi	2
Elkstone Capital Partners	2
Lightstone Ventures	2
SVG Ventures	2
HealthCap	2
Infinity Capital	2
ARCH Venture Partners	2
Tekla Capital Management	1
KBI Biopharma	1
Bank of Ireland Seed and Early Stage Equity fund	1
HBM-MedFocus	1
Medtech Syndicate Nominee	1
Medicxi	1
EQT Life Sciences	1
dlab	1
Earlybird Venture Capital	1
Cambridge Innovation Capital	1
Bpifrance	1
Johnson & Johnson Innovation – JJDC	1
ETV Capital SA	1
MML Capital Partners	1
Covidien	1
Silicon Valley Bank	1
Claret Capital Partners	1
Alimentos Ventures	1
Kreos Capital	1
Novartis Venture Fund	1
Apicap	1
WxNW	1
Blue Wire Capital	1
Cultivian Sandbox Ventures	1

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Advise — Advise Freemium is a ground-breaking automated data analytics for CPG solution. Discover how Advise can assist your Revenue Growth Management.
NUA Surgical — NUA Surgical is an award-winning Irish MedTech company developing innovative solutions in obstetrics and gynaecology.
LaNua Medical — At LaNua Medical it is our mission to develop disruptive image-guided technologies providing safe and effective endovascular solutions.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Supporting communities to grow, investing in businesses to scale and planning for the future of the western region.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Funding Round, Series A
Ireland, United States

Portfolio highlights

Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
Peroptyx — Peroptyx is a platform that provides managed solutions for machine learning. At Peroptyx, they have assembled and pre-screened a qualified network of data evaluators across the globe. They strategically match ideal evaluators with each product to ensure authentic experiences through consistency and appropriate real-world contexts.
CitySwift — CitySwift is a data-driven scheduling and planning technology for urban bus networks. It uses artificial intelligence and machine learning to predict journey times and passenger demand, making routes more efficient. Schedulers can create optimized timetables that take into account traffic, events, and hundreds of other external factors, ensuringon-time performance and increased passenger satisfaction.CitySwift was established in 2016 and is operating in Galway, Ireland.

Irrus Investments is the leading Irish business angel network with international connections. Fueling Irish innovation in medical devices, software, hardware, digital healthcare and life sciences.

Investment focus

Medical Device, Biotechnology, Health Care
Seed, Funding Round, Series A
Ireland, Sweden, United States

Portfolio highlights

Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
CroíValve — CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation
SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes signiﬁcant shortness of breath and chest pain in up to 15% of patients with cancer.

Kernel Capital is the independent manager of The Bank of Ireland Kernel Capital Venture Funds, one of the largest and most active sources of equity finance on the island of Ireland. Kernel leverage their extensive network to enable their portfolio companies recruit the highest caliber people, to break into new international markets and to generaterevenues of scale. It is the only investment firm with venture capital Funds dedicated to both jurisdictions on the Island. Kernel have raised over €210M from investors which including their strategic partner Bank of Ireland, Invest NI, Enterprise Ireland, Galway University Foundation, The University of Limerick Foundation, The New York State Common Retirement Fund and undisclosed Family Offices. Consistently delivering strong financial returns for their investors Kernel have led more than 20 substantial trade sales to NASDAQ, NYSE, and LSE listed corporations.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
Ireland, United Kingdom, France

Portfolio highlights

Cirdan — Cirdan provides highly reliable, innovative LIS & imaging solutions for the acceleration & enhancement of diagnosis, optimized for pathology & clinical lab.
Pretto — Pretto is the only truly transparent online real estate price comparator.Pretto accompanies you until the signing of your loan, free of charge and without commitment.
Pilot Photonics — Welcome to Pilot Photonics, a laser product development company in Dublin, Ireland. We provide optical frequency combs and tunable lasers.

The AIB Seed Capital Fund was established in 2007 to provide venture capital for companies at the seed and early stages of development across a range of sectors throughout the Republic of Ireland. The Fund was established under the Enterprise Ireland Seed and Venture Capital Programme 2007-2012.The Fund has a total of â‚¬30m under managementwith AIB and Enterprise Ireland both committing â‚¬15m. It is managed by experienced managers with extensive expertise in making seed and early stage investments, adding value and facilitating business success.The Fund managers are empowered to make seed investments of up to approximately â‚¬500,000. Furthermore, the Fund has the capacity to make investments in later rounds to support the continued growth of investee companies.The Fund will be managed by Enterprise Equity Venture Capital and the Dublin Business Innovation Centre. This unique partnership brings together extensive regional and investment expertise.Enterprise Equity will evaluate and manage all investments outside the city and county of Dublin, as well as investments that require in excess of â‚¬250,000 from the fund within the city and county of Dublin.Dublin Business Innovation Centre (DBIC) will evaluate and manage all investments within the city and county of Dublin when the initial investment amount required from the Fund does not exceed â‚¬250,000.

Investment focus

Software, Health Care, Medical
Seed, Funding Round, Series A
Ireland, United States, Jersey

Portfolio highlights

NewsWhip — The only real-time media monitoring platform that predicts the stories and topics that will matter in the hours ahead.
Offr — Offr is the new way to buy and sell property, quickly and transparently.
Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.

Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Series C
Ireland, United States, France

Portfolio highlights

MMI — The future of Microsurgery: microinstruments that expand the possibilities of surgical interventions. Wristed robotic microinstruments for unprecedented results in microsurgery.
Mainstay Medical — Mainstay Medical is improving quality of life for patients with chronic low back pain through innovative restorative treatment medical device solutions.
XyloCor Therapeutics — XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively.

Atlantic Bridge is a Growth Equity Firm with a Cross Border Value Add strategy. We invest in deep technology companies in Europe and the US. Our team is made up of successful entrepreneurs and senior technology industry executives and we invest in strong ambitious entrepreneurs and management teams that have the passion and drive to scale up andexploit major growth opportunities. We help our portfolio companies expand and grow internationally through our global platform with our team and offices in London, Dublin, Munich, Paris and Palo Alto.Atlantic Bridge brings together a unique team of technology entrepreneurs, experienced managers, finance professionals, and investment experts. The team contains a wealth of international business experience across Europe, the UK and the US. They have worked together in various capacities for the last 30 years, bringing a true partnership approach to their firm and their investments. Its investors include the founders, leading institutional investors, and private investors with a track record of investment in successful technology companies.Atlantic Bridge has developed a unique and differentiated strategy that focuses on specific technology themes and the implementation of the “Atlantic Bridge Model” for scaling companies internationally. The “Bridge Model” accelerates the scale-up of technology companies in Europe and the US. This approach is highly differentiated and has delivered strong performance results to date.

Investment focus

Software, Information Technology, Artificial Intelligence
Series A, Series B, Funding Round
United States, Ireland, United Kingdom

Portfolio highlights

Mindgard — Mindgard is an AI security company that helps enterprise to test, detect, and respond to cyber threats against their AI models.Given that businesses are increasingly focused on offering AI-driven services such as LLMs, securing this new way of conducting business is equally important. Mindgard ensures that your business can safely and securelymove into the new AI world and continue to protect your digital assets, brand and reputation.Our platform enables enterprise customers to determine, detect, and remediate against any adversarial attack vulnerabilities within all their AI models. This answers the “What is my AI risk?” and “How do I mitigate my AI risk?” questions that currently cannot be answered using traditional Cyber Security platforms. By designing our platform from the ground up to integrate with existing AI and Cyber Security operational tooling, Mindgard can be seamlessly added to your organization, providing repeatable and automated AI model vulnerability testing.The Mindgard platform has been in development for over 4 years based on cutting edge PhD-led, AI & cyber security research, also used by the global Intelligence Community. As well as providing a library of adversarial attacks based on deep research, leveraging our platform that can automate repeated security testing, detection, and response across the entire AI estate. By leveraging the Mindgard platform, our clients free up precious AI and cyber security resources and at the same time understand, detect, and mitigate risks across their entire AI model portfolio, which currently takes too long and is too expensive. Our platform ensures that business can rapidly embrace LLMs and other AI technologies whilst protecting their digital assets, brand, and reputation within the new AI world.
Mindgard Ltd — Mindgard Ltd specializes in providing comprehensive AI security solutions to enterprises. Our operations center around a sophisticated platform designed to determine, detect, and remediate adversarial attack vulnerabilities within AI models. The platform is built on over four years of PhD-led research in AI and cyber security, ensuring advancedprotection that traditional Cyber Security platforms cannot offer.Our platform integrates seamlessly with existing AI and Cyber Security tools, enabling automated and repeatable vulnerability testing across the entire AI estate. This integration allows enterprises to efficiently assess and mitigate risks, optimizing their AI and cyber security resources.Key operational features include: - Automated Security Testing: Utilizing a library of adversarial attacks, our platform conducts thorough and repeated security tests to identify vulnerabilities. - Detection and Response: The platform continuously monitors AI models for threats and provides rapid detection and response capabilities to neutralize potential attacks. - Seamless Integration: Designed for compatibility with existing operational tools, our platform can be easily incorporated into current security infrastructures.Mindgard Ltd's operations ensure that businesses can securely adopt and innovate with AI technologies while protecting their digital assets, brand, and reputation in the evolving AI landscape.
Insight Terra — Insight Terra supports data driven risk management in critical situations where business operations, people and the environment all come together.

Seroba is a leading European life sciences venture capital firm focused on value creation through backing winning innovations in biotech and medtech.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Funding Round
Ireland, United States, United Kingdom

Portfolio highlights

Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
ShiraTronics — ShiraTronics is in the early stages of developing new innovative therapies to combat debilitating migraine headaches. The company is focused on commercializing novel neuromodulation technologies to treat this large unmet clinical need for patients and physicians. ShiraTronics is the first spinout from NuXcel a global medical device acceleratorcompany.
Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea

The European Investment Bank (EIB) offers lending, borrowing, and treasury services primarily within the European Union. It provides project loans for public and private sectors, loans to banks and intermediaries, structured finance products, guarantees, and securitization instruments for debts. Additionally, EIB offers equity and fund investmentproducts, including infrastructure and environmental funds, as well as venture capital funds. EIB also supports microfinance and risk-sharing finance for research and innovation and provides technical expertise for sustainable energy projects. Its services include infrastructure advisory, urban development support, guarantees for transport infrastructure, and funding for public-private partnerships and small- to medium-sized enterprises. The bank serves various sectors, including transportation, energy, health, education, and agriculture.

Investment focus

Biotechnology, Health Care, Energy
Debt Financing, Post-IPO Debt, Funding Round
Germany, France, The Netherlands

Portfolio highlights

Amadix — Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide.The most advancedproduct developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients).Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.
Greenlight Biosciences — Next Generation Crop Protection
Azienda Comprensoriale Acquedottistica — ACA Spa is an integrated water service company.

HBAN is dedicated to raising the profile of business angel investment as an asset class on the island of Ireland and to promote the creation of business angel syndicates.

Investment focus

Health Care, Medical Device, Software
Seed, Funding Round, Series A
Ireland, United Kingdom, United States

Portfolio highlights

Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
Educatly — We help you get into the University of your dreams. We are the only platform with all the information you need to Study Abroad
Quantmatix — Improve the quality, efficiency and timing of your investment decisions. Quantmatix is a systematic tool for professional investors to evaluate instruments, dynamically shape portfolios and drive performance.

HBAN Medtech Syndicate

Investment focus

Medical Device, Medical, Health Care
Seed, Funding Round, Series B
Ireland

Portfolio highlights

FeelTect — FeelTect’s technology, Tight Alright, is a pressure sensing, connected-health device for measuring and monitoring sub-bandage pressure during compression therapy, primarily for the millions of people worldwide with venous leg ulcers (VLUs). Compression is a proven therapy for VLUs, however if it’s applied too loose, it’s ineffective, and if it’stoo tight, it’s dangerous.
Neurobell — NeuroBell develop novel EEG medical devices for early detection and monitoring of neonatal seizures.
SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes signiﬁcant shortness of breath and chest pain in up to 15% of patients with cancer.

We invest in entrepreneurs with the ambition to create world-class companies of scale.

Investment focus

Medical Device, Health Care, Big Data
Seed, Series A, Funding Round
Ireland, United States

Portfolio highlights

CroíValve — CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation
ProVerum Medical — ProVerum Medical is an early stage medical device startup for the treatment of Benign Prostatic Hyperplasia (BPH).
Tympany Medical — Tympany Medical is a Needs-driven, Innovative MedTech StartUp based in the West of Ireland

Technology-focused, investing capital and expertise to fuel growth in the most promising ideas and companies. Raised c.€600m across multiple funds and invest from seed to growth.We look for companies with potentially cutting-edge, category-defining businesses in markets including application software, IT infrastructure, communications, Internetand mobile. We help founders create and scale businesses globally. We work as a small team with diverse strengths accessing a community of over 200 founders. The teams and companies we back scale their investor base as they scale their business execution and ambition. We work closely with them in this process. Over the past 25 years have built a broad network of US and European investors and founders that share our vision and approach.Act is based in Dublin, Ireland.Our most recent funds are supported by the European Investment Fund.

Investment focus

Software, Information Technology, SaaS
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Trustap — Learn how we make buying & selling online safe & secure, every time. Create an account for free today!
Advise — Advise Freemium is a ground-breaking automated data analytics for CPG solution. Discover how Advise can assist your Revenue Growth Management.
Mavarick AI — Explore Mavarick AI's Carbon Accounting Software Platform. Get accurate carbon emissions accounting data and generate auditable reports with ease.

Boole Investment Syndicate invests in new technology start-up's with scalability.

Investment focus

Medical Device, SaaS, EdTech
Seed, Funding Round
Ireland, United States

Portfolio highlights

Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
FeelTect — FeelTect’s technology, Tight Alright, is a pressure sensing, connected-health device for measuring and monitoring sub-bandage pressure during compression therapy, primarily for the millions of people worldwide with venous leg ulcers (VLUs). Compression is a proven therapy for VLUs, however if it’s applied too loose, it’s ineffective, and if it’stoo tight, it’s dangerous.
SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes signiﬁcant shortness of breath and chest pain in up to 15% of patients with cancer.

The Yield Lab Europe is a €50m early stage Agrifood and Ag Tech fund which comprises an accelerator and a larger follow-on fund, investing in high tech companies with the potential to significant disrupt and improve our current systems of global food production, and to improve the environmental sustainability of the industry. The main fund invests€1m each into 10-12 companies over several follow on rounds, with the strongest accelerator companies expected to progress to the main fund. The Yield Lab Europe is also part of a global network of Agrifood Tech funds, with global headquarters in St Louis USA, and sister funds in LATAM and Singapore.

Investment focus

AgTech, Agriculture, Biotechnology
Seed, Series A, Funding Round
Ireland, France, United Kingdom

Portfolio highlights

Oligofeed — We developed a supplement boosting bee immunity. Our non-toxic bee-feeding product reduces bee mortality and improves the production of the hives.
Marama Labs — Marama Labs provides an integrated chemical analysis platform that empowers customers to optimize their production processes and match their products and brands to customer needs, with ease.
Micron AgriTech — Micron Agritech, driving the future of sustainable animal health. Run a FEC worm or fluke test with your phone and get results in minutes.

Furthr VC invests in transformative tech. Furthr Venture Capital invests in scalable, early-stage companies. We help Ireland's next generation of technology.

Investment focus

Medical, Medical Device, Health Care
Seed, Funding Round, Pre-Seed
Ireland

Portfolio highlights

Trustap — Learn how we make buying & selling online safe & secure, every time. Create an account for free today!
Neurobell — NeuroBell develop novel EEG medical devices for early detection and monitoring of neonatal seizures.
LaNua Medical — At LaNua Medical it is our mission to develop disruptive image-guided technologies providing safe and effective endovascular solutions.

We work with leading corporations, startups, universities, and growers to solve the biggest challenges facing the agtech and foodtech industries.

Investment focus

AgTech, Agriculture, Farming
Pre-Seed, Seed, Funding Round
United States, Canada, Ireland

Portfolio highlights

FarmWise — FarmWise provides technology-based services that allow farmers to streamline farm operations and increase food production efficiency.
Napigen — We are the genome editing company specialized for mitochondrial engineering. We address unmet needs of future food supplies by creating hybrid crop plants to boost their yields to an unprecedented level. The company’s technology creates robust male sterile lines that are ideal over conventional lines because of their stability and elitebackgrounds. This allows the production of non-GM hybrid seeds in crop plants that are currently mostly non-hybrid such as wheat. Our technology solution is expected to fulfill the highest level of public acceptance and aspiration.
Iamus Technologies — Iamus Technologies Limited is an Artificial Intelligence & Robotics company based in Ireland that has developed poultry specific robotic technology that empowers poultry farmers to make better and safer production decisions. Over the last 2 years we have been working globally with poultry processors in identifying KPIs that our robots cancontinuously gather on the ground in poultry sheds and feedback instantly to both producer and the relevant personnel back at the processing plant. Results to date are impressive with automatic and accurate data recovery from the birds on every part of the floor and analysis with real-time intervention now possible. These factors are key in addressing the growing demands of modern, intensive broiler production with the Iamus robot & platform meeting these requirements.

Enterprise Equity (or EEVC) is an excellent for providing capital to early stage and expanding business throughout Ireland.

Investment focus

Software, Information Technology, Medical Device
Funding Round, Seed, Series B
Ireland, United States, United Kingdom

Portfolio highlights

Phorest — Join 8000+ spas, barbers, hair, beauty and nail salon owners using the #1 management, scheduling, POS and appointment booking system. Try Phorest now!
SurgaColl — SurgaColl Technologies is a medical device company developing novel tissue regeneration products for the surgical treatment of diseases of the bone, cartilage and other human tissue. Based on technology developed at the Tissue Engineering Research Group (TERG) of the Royal College of Surgeons in Ireland (RCSI), headed by Professor Fergal O’Brien,the company aims to become a leader in the field of regenerative medical devices.
Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.

Discover start-up investing made simple. Access VC-led rounds, build your portfolio, and unlock growth at Ascentifi

Investment focus

Medical, Health Care, Medical Device
Funding Round, Series A
Ireland

Portfolio highlights

CroíValve — CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation
Vertigenius — Vertigenius designs and deploys customized exercises using an easy-to-use clinician portal and even uses a Vertigenius head sensor to consult and manage patients with dizziness and imbalance.
X-BOLT Orthapaedics — X-Bolt Trauma Solutions for osteoporotic bone fixation. FDA 510(k) approved. Clinical studies include the WHITE One (n=100) and WHITE Four (n=1,140) randomized control trials.

Elkstone is an investment firm, focusing on entrepreneurs, senior executives, institutional LPs, the venture community, and the Irish diaspora.The objective of the organization is to boost the economic value and overall well-being of the island of Ireland by expanding a network, facilitating deserving investments, and delivering excellentinvestment performance.

Investment focus

Software, Health Care, Medical
Seed, Series A, Funding Round
Ireland, United Kingdom, United States

Portfolio highlights

Advise — Advise Freemium is a ground-breaking automated data analytics for CPG solution. Discover how Advise can assist your Revenue Growth Management.
LaNua Medical — At LaNua Medical it is our mission to develop disruptive image-guided technologies providing safe and effective endovascular solutions.
Jentic Technology — Jentic Technology builds integration layer for AI, enabling developers to connect agents to the World.

Lightstone Ventures is a global venture capital firm that invests in personalized medicines and targeted therapeutics. Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing inbreakthrough life science companies during a time of unique opportunity in space.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Ireland, Singapore

Portfolio highlights

FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Cala Health — Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is an essential tremor, adisease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.
Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology

We are a Venture & Innovation Platform Advancing the Food & Agriculture Industries We work with leading corporations, startups, universities, and growers to solve the biggest challenges facing the food and agriculture industries.

Investment focus

AgTech, Agriculture, Farming
Pre-Seed, Seed, Funding Round
United States, Canada, Ireland

Portfolio highlights

scoutlabs — We're building the world's densest digital trap network to accurately gauge insect pest pressure. This helps millions of farmers in precisely combating crop-eating insects, accelerating a transition to more sustainable methods. Good for the farmer, the environment and for our food security
Verdi Expeditions — Verdi is building the world's first truly scalable platform for farm automation. We work with the world's largest food brands to grow better and more sustainable crops.
Heritable Agriculture — Making plants programmable

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United States, Sweden, France

Portfolio highlights

Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.
SynOx Therapeutics — SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland.

Infinity Capital are hypothesis-driven investors - constantly calibrating ideas through a Silicon Valley/technology network that they've been building for over two decades. Their extensive technology and operating backgrounds, combined with over a dozen years each of successful startup investing, have been essential in buildingcredibility and a reputation that resonates with entrepreneurs.

Investment focus

Semiconductor, E-Commerce, Electronics
Series B, Funding Round, Series D
United States, Ireland, Canada

Portfolio highlights

AltraTech — Next Generation Molecular Detection Discover Altratech Next Generation Molecular Detection Discover Altratech At Altratech, our mission is to enable next generation molecular detection.
BioSapien — BioSapien is a pre-clinical biotech company developing novel biodegradable implantable products that deliver active pharmaceutical ingredients (APIs) for oncology indications with reduced systemic side effects. The applications for this technology are currently under investigation for pancreatic cancer and lung cancer. The intended pipeline ofindications is expected to expand into other cancers such as colorectal, breast, and stomach cancers. BioSapien's 3D-printed MediChip delivers FDA-approved toxic high-dose systemic therapies in a localized slow-release biodegradable mesh which is able to target tissues while improving patients' quality of care and life.
Core Starters — Core Starters services startups and investors through blockchain-based decentralized services to solve real problems.

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, China, United Kingdom

Portfolio highlights

Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
Kardigan — Kardigan is building the heart health company of the future focused on developing medicines to make cardiovascular disease curable, preventable, and no longer the leading cause of death.
Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.

We are dedicated to helping investors reach their investment goals. Get in touch with our team to explore abrdn's investment options.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Series A
United States, Switzerland, France

Portfolio highlights

Oculis — Experience the Future of Eye Care: Oculis, a Clinical Biopharmaceutical Innovator, Pioneering Breakthrough Treatments for Ophthalmic Diseases & Transforming Lives Globally.
Amolyt Pharma — AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
Endeavor BioMedicines — Endeavor BioMedicines is a clinical-stage biotechnology company developing transformational medicines for life-threatening diseases.

KBI Biopharma Inc. is a global contract development and manufacturing organization (CDMO / CMO) offering Cell Line Development, Process Analytical & Formulation Development, Clinical & Commercial Manufacturing, and more.

Investment focus

Biotechnology, Life Science, Medical
Seed, Series A, Series D
United States, Ireland

Portfolio highlights

Absci — A better, faster path to new medicines. We translate ideas into drugs with an AI-powered approach to biologic drug discovery and cell line development.
GlycoSeLect — GlycoSeLect Ltd specialises in the development and production of Recombinant Prokaryotic Lectins (RPLs).
Comera Life Sciences — ReForm Biologics is an engineering superior biotherapeutic formulation for fragile patients. Its proprietary technology provides patented, FDA-friendly excipients for a wide range of therapeutic biologics. Using its platforms, drug companies can make life-saving medicines easier to administer, less immunogenic, more stable, and more efficient toproduce. It was founded in 2014 and is based in Woburn, Massachusetts.

The Bank of Ireland Seed and Early Stage Equity fund is a joint fund built with contributions from the Bank of Ireland, the University of Limerick Foundation, and government-backed The seed fund will invest in export-oriented high potential firms that operate in the technology, food and financial services sectors, inaddition to supporting patent and patent pending projects within Irish universities, targeting investments between EUR 100K-500K. The new fund comprises of a â‚¬17 million investment by Bank of Ireland, along with funding of â‚¬8 million from Enterprise Ireland and â‚¬ 1million by the University of Limerick Foundation. It will be managed by

Investment focus

Software, Photography, Solar
Funding Round, Seed, Series A
Ireland

Portfolio highlights

Pulsate — Engage digitally banked customers effectively with Pulsate: tools for deeper, impactful relationships beyond branch interactions.
LegitFit — LegitFit is there to help you from first sale to scale! Our leading software solution is everything you need to run & grow a successful business. It's easy to use, affordable, and integrates powerful tools for bookings, payments, and communication!
Certification Europe — Certification Europe offers ISO Certification, Inspection and ISO Training solutions to drive compliance for our clients!

HBM-MedFocus

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B
Ireland, United States

Portfolio highlights

Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
Viseon — Viseon is a privately held medical device company committed to developing proprietary technology for use in Minimally Invasive Spine Surgery (MISS) procedures. Viseon has progressed rapidly over the past 6-months, having developed a unique array of devices to improve the procedural and clinical outcomes of many minimally invasive spine surgeryprocedures. In addition to rapid product development of its initial products, Viseon has assembled a world-class Scientific Advisory Board of leading MISS physicians, amassed 13 patents to solidify its intellectual property platform, and completed a series of pre-clinical studies supporting initial human-use, scheduled to begin soon.Viseon was founded in early 2017 as a spin-out from Rebound Therapeutics Corporation.

Medtech Syndicate Nominee

Investment focus

Medical, Health Care, Medical Device
Seed, Series A, Funding Round
Ireland

Portfolio highlights

Kite Medical — Kite medical has developed a novel device for detecting Kidney Reflux in children with Urinary Tract Infections. The non-invasive diagnostic solution for kidney reflux removes the need for complicated procedures and a hospital visit. Kidney reflux is the most common urological disorder in childhood, affecting up to three per cent of young children.It is most prevalent from six months to five years of age. The condition may resolve as the child gets older, but left undiagnosed and untreated it can lead to permanent kidney damage and ultimately to kidney failure.
Signum Surgical — Founded in 2014 by Eoin Bambury and Moshe Zilversmit, Signum Surgical is a medtech platform striving to develop technology that could cure perianal fistula. Bambury and Zilversmit, who met on the BioInnovate Ireland programme at NUI Galway, recognised a lack of innovation surrounding the treatment of perianal fistulas (small tunnels that developbetween the end of the bowel and the skin near the anus). The device developed by Signum Surgical is implanted post-surgery to prevent reinfection and to allow a faster healing process.

Medicxi is an investment firm that focuses on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Seed
United States, United Kingdom, The Netherlands

Portfolio highlights

Rapt Therapeutics — RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selectivesmall molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development.
Vicebio — Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses. Vicebio is a biopharmaceutical business that creates innovative vaccinations to prevent potentially fatal respiratory viral infections.
Ottimo Pharma — Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden.

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.

Early-stage venture capital and resources for startups exploring new frontiers in web3, decentralization, and blockchain technology.

Investment focus

Blockchain, Software, Information Technology
Seed, Pre-Seed, Convertible Note
United States, Canada, Germany

Portfolio highlights

FleetOperate — FleetOperate is a truck driver marketplace platform that enables drivers to provide on-demand driving services to carriers and shippers. The company's platform offers booking shipment from a particular location with registered truck drivers and permits tracking of their location eliminating the problem of driver shortages, driver turnover, andunseated trucks while maintaining low costs, enabling people to transport their essentials with ease. The carriers and shippers avail Driver-as-a-Service to solve the problem of driver shortages, driver turnover, and unseated trucks while maintaining low costs.FleetOperate was founded in 2018 and is headquartered in Winnipeg, Manitoba.
Light Protocol — Light allows developers to reduce the cost of on-chain state by orders of magnitude without sacrificing the security and performance of the Solana L1.
WeatherXM — Join WeatherXM's global network powered by blockchain. Earn WXM tokens with accurate, hyperlocal forecasts for agriculture, energy, and more.

Founded in 1997, Earlybird invests in all development and growth phases of technology companies. Among the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources but also strategic support plus access to an international network and capital markets. With EUR 2 billion under management,eight IPOs and 30 trade sales, Earlybird is one of the most established and active venture capital firms in Europe.

Investment focus

Software, Information Technology, Health Care
Series A, Seed, Series B
Germany, United States, United Kingdom

Portfolio highlights

eyva.ai — The decisonOS for beauty and personal care
GEMMABio — GEMMABio, a new therapeutics company, will serve as the research and innovation arm to speed the research of and global access to life-changing advanced therapies for those living with rare diseases.
Upvest — Upvest empowers financial institutions to offer investment products in their app with a modular, scalable, and accessible API. Upvest brings together everything that’s required to offer a broad range of investment products on the website and app. They are connected to the world’s leading asset providers and exchanges to provide the bestinvestments, at the best prices and execution speed.

Cambridge Innovation Capital backs life sciences and technology companies with an affiliation to Cambridge, Europe’s capital for innovation. As a preferred investor for the University of Cambridge, they have unparalleled access to investment opportunities in the ecosystem.Since our inception in 2013, they have raised £275 million to invest indisruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, the internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health, and genomics/proteomics.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United Kingdom, United States, Ireland

Portfolio highlights

Forefront RF — Forefront RF tunable duplexer aims to expand the accessibility and global market reach of all mobile devices by simplifying RFFE design.
Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.

Investment focus

Software, Information Technology, Health Care
Seed, Funding Round, Series A
France, United States, Switzerland

Portfolio highlights

Swan — Use Swan's APIs to embed white-labeled banking features like accounts, cards, and IBANs into your workflows and UX.
CROWN — CROWN is modernizing procurement negotiations through ethical eAuctions.
Keey Aerogel — Home - Welcome to the homepage of KEEY Aerogel ! Discover our company, our products and our know-how in aerogels.

JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Israel, France

Portfolio highlights

Citryll — Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
Cala Health — Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is an essential tremor, adisease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.
G.I. Windows — G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States.

Get this domain name before someone else does. Quick and painless shopping. Affordable payment options available.

Investment focus

TV, Auctions, Computer
Funding Round
Ireland, United States, United Kingdom

Portfolio highlights

123.TV — German television channel, 123TV organizes cross-media auctions (TV and internet) on consumer products, for a public of all generations. The auction is reversed in the sense that the price fixed in advance to steady decreases over time until the amounts passed.
Nallatech — Nallatech Ltd. provides FPGA computing solutions for defense and security market. It offers FPGA computing motherboards, FPGA computing modules, software and IP cores, and HPC products. The company offers its products through sales team in the United States and the United Kingdom. Nallatech Ltd. was formerly known as Nallatech Worldwide Limitedand changed its name in May 2008. The company was founded in 1993 and is based in Glasgow, United Kingdom with regional offices in San Jose, Los Angeles, Philadelphia, and Boston. As of May 2, 2008, Nallatech Ltd. operates as a subsidiary of Interconnect Systems, Inc.
Stokes Bio — Stokes Bio develops and distributes microfluidic technology to its clients. It was founded in 2005 and is based in Ireland. It was acquired by Life Technologies in 2010.

MML Capital Partners is an independent investment firm, with over twenty years of history, focused on providing capital to businesses for expansion/acquisitions, management-led equity deals, recapitalisations and buy-outs.

Investment focus

Manufacturing, Packaging Services, Information Technology
Private Equity, Funding Round, Series A
United Kingdom, France, United States

Portfolio highlights

RAVL — Step into the future with RAVL and our revolutionary financial service technology solutions. We're not just building tech; we're crafting the future of financial services. Unleashing potential, one innovative solution at a time. Let's strategize, deliver, and repeat excellence together.
SCPACK GROUP — SCPACK GROUP is a packaging and containers manufacturing company for wine, cosmetics and more.
Ross-shire Engineering — Trusted water technology solutions and products for purifying drinking water, recycling effluent and cleaning water in industrial processes.

Covidien plc engages in the development, manufacture, and sale of healthcare products for use in clinical and home settings. Segments The company operates its businesses through four segments: Medical Devices includes the development, manufacture and sale of endomechanical instruments, soft tissue repair products, energy devices, oximetry andmonitoring products, airway and ventilation products, vascular devices, SharpSafety products, clinical care products and other medical device products; Imaging Solutions includes the development, manufacture and marketing of radiopharmaceuticals and contrast products; Pharmaceutical Products includes the development, manufacture and distribution of dosage pharmaceuticals and active pharmaceutical ingredients; and Medical Supplies includes the development, manufacture and sale of nursing care products, medical surgical products and original equipment manufacturer products (OEM). The Medical Device segment develops, manufactures and sells an array of products which the company categorizes in the following product groups: - Endomechanical Instrumentsâ includes its laparoscopic instruments and surgical staplers. - Soft Tissue Repair Productsâ includes its sutures, mesh and biosurgery products. - Energy Devicesâ includes its vessel sealing, electrosurgical and ablation products and related capital equipment. Oximetry and Monitoring Productsâ includes its sensors, monitors and temperature management products. Airway and Ventilation Productsâ€”includes its airway, ventilator, breathing systems, sleep and inhalation therapy products. Vascular Devicesâ ”includes its compression and vascular therapy products. SharpSafety Productsâ includes its needles, syringes and sharps disposable products. Clinical Care Productsâ includes its urology, enteral feeding and other advanced woundcare products.

Investment focus

Health Care, Therapeutics, Biotechnology
Series A
Ireland

Portfolio highlights

FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

Silicon Valley Bank is the financial partner of the innovation economy; helping individuals and investors in the innovation ecosystem achieve extraordinary outcomes.

Investment focus

Software, Health Care, Biotechnology
Debt Financing, Series B, Series A
United States, United Kingdom, Canada

Portfolio highlights

Chimerix — Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA(dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerixâ€™s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.
Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.
TScan Therapeutics — Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien velit, aliquet eget commodo nec, auctor a sapien. Nam eu neque vulputate diam rhoncus faucibus. Curabitur quis varius libero.

Claret Capital provides specialty debt financing to European growth businesses, predominantly in the technology, life sciences and environmental sectors. Typical loan sizes range from €1M-€40M with the flexibility to do larger transactions opportunistically.They look for investment opportunities in high growth business with proven managementteams in need of capital to fuel organic growth, acquisitions, equipment purchases, bridge loans and various forms of recapitalization.

Investment focus

Software, Information Technology, Mobile
Debt Financing, Funding Round, Series A
United Kingdom, Germany, United States

Portfolio highlights

Abivax — Abivax recently presented impressive 9-month interim extension data from studies of ABX464 in ulcerative colitis during an oral presentation at DDW 2019, demonstrating a continued duration of beneficial effect in patients after 11-months of treatment. View the conference presentation, here:
Holidu — Holidu is one of the fastest-growing travel tech companies worldwide that aims to finally make the search and booking of vacation rentals easy. Its search engine uses proprietary image recognition technology to compare the prices of millions of rental properties across hundred of websites including Airbnb, Booking.com, and Homeaway. This enablesusers to quickly find the ideal accommodation and to save up to 55% on their bookings. It was founded in 2014 by brothers Johannes and Michael Siebers and is headquartered in Munich, Bayern, Germany.
Exoticca — Exoticca develops an online platform intended to facilitate travel booking. The company's platform offers holiday packages which includes flights, accommodation, meals, guides and private transports, for exotic locations all around the world, enabling travelers to book travel packages online at competitive prices.

Accelerate innovation in aquaculture feed and technology.

Investment focus

Farming, Aquaculture, Therapeutics
Seed
Ireland

Portfolio highlights

MicroSynbiotiX — Microsynbiotix, an Irish-based Biotechnology company making microalgal oral vaccines for aquaculture

Kreos Capital is Europe's largest and leading provider of growth debt to high-growth companies with revenues up to €150 million. Since 1998, as the pioneer growth debt provider across the UK, Western Europe, Scandinavia and Israel: Kreos has completed nearly 450 transactions and committed €1.8 billion in 14 different countries. Kreos has aproven track record of adding value to portfolio companies and helping them to grow with additional capital and flexibility throughout their business cycle whilst working closely with both the portfolio company management team and their equity sponsors.The Kreos global team has extensive debt financing, management and equity investing experience, covering the pan-European market from its locations in London, Tel Aviv and Stockholm.Kreos is a value added partner, able to offer additional capital and more flexibility with lower equity dilution. Kreos's international team has extensive entrepreneurial, debt financing and equity investing experience, covering all local European markets from its locations in London, Tel Aviv and Stockholm.

Investment focus

Biotechnology, Health Care, Software
Debt Financing, Series B, Post-IPO Debt
United Kingdom, Germany, United States

Portfolio highlights

Abivax — Abivax recently presented impressive 9-month interim extension data from studies of ABX464 in ulcerative colitis during an oral presentation at DDW 2019, demonstrating a continued duration of beneficial effect in patients after 11-months of treatment. View the conference presentation, here:
BiolineRx — BioLineRx is building a best-in-class pipeline designed to deliver meaningful therapeutic benefit to patients with certain cancers and rare diseases.
Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program.We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. SectorsNew therapeutics & platformsMedical devices/implantsDiagnostics/biomarkersDrug delivery/biopolymersGeographyUSA/CanadaEuropeSwitzerlandAsia/Pacific

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.
Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.

Apicap offers investment and co-investment solutions for managers, wealthy private clients and institutional investors.

Investment focus

Software, Information Technology, Mobile
Funding Round, Series A, Series B
France, United States, Turkey

Portfolio highlights

Crowdaa — Crowdaa is a mobile-only music store where producers decide how to distribute and monetise their content.
Feelbat — FEELBAT - Feelbat
Karma Koma — Karma Koma is specializes in retail and French and international distribution with multi-brand resellers.

WxNW operates as an investment firm.

Investment focus

Sales, Consumer, Marketing
Seed, Funding Round
Ireland

Portfolio highlights

Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
UrbanFox — Discover cutting-edge AI data processing solutions tailored to your needs. Elevate your business with innovative technology, personalized service, and a commitment to excellence.

Investing globally in Frontier & Consumer businesses at pre-seed or seed.

Investment focus

Software, Advanced Materials, Art
Seed, Pre-Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Faircraft — A sustainable, lab-grown alternative to animal leather.
Praktika — Automated 1-1 tutorship experience with generative AI Avatar tutors
River Platform Company — Orchestrate IRL events at massive scale by leveraging volunteer hosts from your community. Monetize community events with our sponsorship marketplace.

Cultivian Sandbox is a venture capital firm focused on building next-generation disruptive agriculture and food technology companies capable of generating superior returns. As early investors and active board members, we employ a hands-on approach to building companies and are often directly involved in setting company strategy, recruiting keyexecutives, and raising additional capital. Much more than simply a financial resource, we are capable of delivering tremendous value though active collaboration with our strategic partners and network, which are unparalleled in the agriculture and food industries.As both experienced operating managers and venture investors we add value to portfolio companies both through our highly skilled team and extensive industry network. Our investment team combines the domain expertise and investment experience from Cultivian Ventures and Sandbox Industries. Our expertise in sourcing, evaluating, closing, managing and ultimately exiting successful equity investments positions us not only to build stronger businesses, but reshape industries.

Investment focus

Agriculture, Biotechnology, Farming
Series A, Series B, Seed
United States, Canada, Germany

Portfolio highlights

Full Harvest — Waste less, profit more. Source imperfect and surplus fruits and vegetables up to 10-30% off.
Debut — Debut Biotech is a biotechnology company that focuses on providing specialty enzyme solutions combined with continuous manufacturing. It combines the power of enzymes with continuous manufacturing to create and modify small and large molecules for a wide range of industries and applications.The company was founded in 2019 and is based in SanDiego, California.
Leaf Agriculture — Simplify farm data integration and management with Leaf's unified agriculture API. Connect fields, operations, imagery, weather, and more from multiple providers via a single source.